1
|
Ferlay J, Autier P, Boniol M, Heanue M,
Colombet M and Boyle P: Estimates of the cancer incidence and
mortality in Europe in 2006. Ann Oncol. 18:581–592. 2007.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics. CA Cancer J Clin.
58:71–96. 2008.
|
3
|
DeRienzo DP, Greenberg SD and Fraire AE:
Carcinoma of the larynx. Changing incidence in women. Arch
Otolaryngol Head Neck Surg. 117:681–684. 1991. View Article : Google Scholar : PubMed/NCBI
|
4
|
Chen YJ, Chang JT, Liao CT, Wang HM, Yen
TC, Chiu CC, Lu YC, Li HF and Cheng AJ: Head and neck cancer in the
betel quid chewing area: recent advances in molecular
carcinogenesis. Cancer Sci. 99:1507–1514. 2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Rempel SA, Golembieski WA, Ge S, Lemke N,
Elisevich K, Mikkelsen T and Gutierrez JA: SPARC: a signal of
astrocytic neoplastic transformation and reactive response in human
primary and xenograft gliomas. J Neuropathol Exp Neurol.
57:1112–1121. 1998. View Article : Google Scholar : PubMed/NCBI
|
6
|
Seno T, Harada H, Kohno S, Teraoka M,
Inoue A and Ohnishi T: Downregulation of SPARC expression inhibits
cell migration and invasion in malignant gliomas. Int J Oncol.
34:707–715. 2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
Ledda F, Bravo AI, Adris S, Bover L,
Mordoh J and Podhajcer OL: The expression of the secreted protein
acidic and rich in cysteine (SPARC) is associated with the
neoplastic progression of human melanoma. J Invest Dermatol.
108:210–214. 1997. View Article : Google Scholar : PubMed/NCBI
|
8
|
Horie K, Tsuchihara M and Nakatsura T:
Silencing of secreted protein acidic and rich in cysteine inhibits
the growth of human melanoma cells with G arrest induction. Cancer
Sci. 101:913–919. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Sato N, Fukushima N, Maehara N,
Matsubayashi H, Koopmann J, Su GH, Hruban RH and Goggins M:
SPARC/osteonectin is a frequent target for aberrant methylation in
pancreatic adenocarcinoma and a mediator of tumor-stromal
interactions. Oncogene. 22:5021–5030. 2003. View Article : Google Scholar : PubMed/NCBI
|
10
|
Di Martino JF, Lacayo NJ, Varadi M, Li L,
Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC and Dahl GV:
Low or absent SPARC expression in acute myeloid leukemia with MLL
rearrangements is associated with sensitivity to growth inhibition
by exogenous SPARC protein. Leukemia. 20:426–432. 2006.
|
11
|
Socha MJ, Said N, Dai Y, Kwong J,
Ramalingam P, Trieu V, Desai N, Mok SC and Motamed K: Aberrant
promoter methylation of SPARC in ovarian cancer. Neoplasia.
11:126–13512. 2009.PubMed/NCBI
|
12
|
Yang E, Kang HJ, Koh KH, Rhee H, Kim NK
and Kim H: Frequent inactivation of SPARC by promoter
hypermethylation in colon cancers. Int J Cancer. 121:567–575. 2007.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Cheetham S, Tang MJ, Mesak F, Kennecke H,
Owen D and Tai IT: SPARC promoter hypermethylation in colorectal
cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC
expression and improve therapy response. Br J Cancer. 98:1810–1819.
2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Bull-Phelps SL, Carbon J, Miller A,
Castro-Rivera E, Arnold S, Brekken RA and Lea JS: Secreted protein
acidic and rich in cysteine as a regulator of murine ovarian cancer
growth and chemosensitivity. Am J Obstet Gynecol. 200:180–187.
2009.PubMed/NCBI
|
15
|
Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY,
Wieand HS, Shin HJ, Chen A, Khuri FR and Shin DM: Tumor growth
inhibition by simultaneously blocking epidermal growth factor
receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer
Res. 11:6261–6269. 2005. View Article : Google Scholar : PubMed/NCBI
|
16
|
Olek A, Oswald J and Walter J: A modified
and improved method for bisulphite based cytosine methylation
analysis. Nucleic Acids Res. 24:5064–5066. 1996. View Article : Google Scholar : PubMed/NCBI
|
17
|
Maruya S, Issa JP, Weber RS, Rosenthal DI,
Haviland JC, Lotan R and El-Naggar AK: Differential methylation
status of tumor-associated genes in head and neck squamous
carcinoma: incidence and potential implications. Clin Cancer Res.
10:3825–3830. 2004. View Article : Google Scholar
|
18
|
Bennett KL, Karpenko M, Lin MT, Claus R,
Arab K, Dyckhoff G, Plinkert P, Herpel E, Smiraglia D and Plass C:
Frequently methylated tumor suppressor genes in head and neck
squamous cell carcinoma. Cancer Res. 68:4494–4499. 2008. View Article : Google Scholar : PubMed/NCBI
|
19
|
Bennett KL, Lee W, Lamarre E, Zhang X,
Seth R, Scharpf J, Hunt J and Eng C: HPV status-independent
association of alcohol and tobacco exposure or prior radiation
therapy with promoter methylation of FUSSEL18, EBF3, IRX1, and
SEPT9, but not SLC5A8, in head and neck squamous cell carcinomas.
Genes Chromosomes Cancer. 49:319–326. 2010.
|
20
|
Choi P, Jordan CD, Mendez E, Houck J, Yueh
B, Farwell DG, Futran N and Chen C: Examination of oral cancer
biomarkers by tissue microarray analysis. Arch Otolaryngol Head
Neck Surg. 134:539–546. 2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
Chin D, Boyle GM, Williams RM, Ferguson K,
Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG and Coman
WB: Novel markers for poor prognosis in head and neck cancer. Int J
Cancer. 113:789–797. 2005. View Article : Google Scholar : PubMed/NCBI
|
22
|
Suzuki M, Hao C, Takahashi T, Shigematsu
H, Shivapurkar N, Sathyanarayana UG, Iizasa T, Fujisawa T,
Hiroshima K and Gazdar AF: Aberrant methylation of SPARC in human
lung cancers. Br J Cancer. 92:942–948. 2005. View Article : Google Scholar : PubMed/NCBI
|
23
|
Chen G, Tian X, Liu Z, Zhou S, Schmidt B,
Henne-Bruns D, Bachem M and Kornmann M: Inhibition of endogenous
SPARC enhances pancreatic cancer cell growth: modulation by
FGFR1-III isoform expression. Br J Cancer. 102:188–195. 2010.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Tang MJ and Tai IT: A novel interaction
between procaspase 8 and SPARC enhances apoptosis and potentiates
chemotherapy sensitivity in colorectal cancers. J Biol Chem.
282:34457–34467. 2007. View Article : Google Scholar
|